Animec 0.8 mg/ml Oral Solution for Sheep

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

Ivermectin

Disponível em:

Chanelle Pharmaceuticals Manufacturing Limited

Código ATC:

QP54AA01

DCI (Denominação Comum Internacional):

Ivermectin

Dosagem:

0.8 milligram(s)/millilitre

Forma farmacêutica:

Oral solution

Tipo de prescrição:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapêutico:

Sheep

Área terapêutica:

ivermectin

Indicações terapêuticas:

Endectoparasiticides

Status de autorização:

Authorised

Data de autorização:

2009-05-29

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Animec 0.8 mg/ml Oral Solution for Sheep.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Each ml contains:
Ivermectin
0.8mg
EXCIPIENT(S):
Benzyl Alcohol (E1519)
28.6mg
Butylhydroxyanisole (E320)
0.10 mg
Propyl Gallate (E310)
0.10 mg
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oral Solution.
A transparent, yellow coloured solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of infections with the following parasites:
NEMATODES
GASTROINTESTINAL ROUNDWORMS (adult and fourth larval stage)
_Haemonchus contortus_
_Teladorsagia circumcincta_
_Trichostrongylus_ spp.
_Cooperia_ spp.
_Nematodirus_ spp.
Including_ N. battus_
_Strongyloides papillosus_
_Chabertia ovina_
LUNGWORMS(adult and fourth larval stage)
_Dictyocaulus filaria_
ARTHROPODS
NASAL BOT (all larval stages)
_Oestrus ovis_
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active
ingredient or any of the excipients.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_2_
_/_
_0_
_5_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_0_
_6_
_6_
_9_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk of development of resistance and
could ultimately result in ineffective therapy: